MSB 1.34% $1.51 mesoblast limited

$5.8 Billion, page-16

  1. 16,463 Posts.
    lightbulb Created with Sketch. 774
    Can i ask what good interim results are we looking for that will give the FDA reasons for stopping the trial earlier than the expected finish date of June 2018. Will it be based on primary outcome measures, secondary outcome measures or both. https://clinicaltrials.gov/ct2/show/record/NCT02032004
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.